classical complement pathway

Trials

144 participants · First posted Apr 17, 2024

Enrolling By Invitation

NCT06723106

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

144 participants · First posted Dec 9, 2024

Unknown

NCT02826057

The Complement Lectin Pathway After Cardiac Arrest

82 participants · First posted Jul 7, 2016

Drugs

View all 127 →

Biotech

Investigational

Riliprubart

Manufacturer: Sanofi

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

classical homocystinuria

Bifunctional complement inhibitor

Organizations

View all 19 →

Pathway Therapeutics, Inc.

United States

Annexon

United States

Erasca

United States

News

View all 5663 →

last year

Dianthus Therapeutics Completes Enrollment in Phase 2 MaGic Trial for Generalized Myasthenia Gravis Treatment

last month

Tanruprubart Demonstrates Rapid Recovery in Guillain-Barré Syndrome, Supporting 2026 BLA Submission

last year

Trials

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

The Complement Lectin Pathway After Cardiac Arrest

Drugs

Riliprubart

classical homocystinuria

Bifunctional complement inhibitor

Organizations

Pathway Therapeutics, Inc.

Annexon

Erasca

News

Dianthus Therapeutics Completes Enrollment in Phase 2 MaGic Trial for Generalized Myasthenia Gravis Treatment

Tanruprubart Demonstrates Rapid Recovery in Guillain-Barré Syndrome, Supporting 2026 BLA Submission

Ruxoprubart Receives FDA IND Clearance for Phase II Trials in IgAN and Dermatomyositis